Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Non Operating Income (2016 - 2025)

Cytokinetics (CYTK) has disclosed Non Operating Income for 16 consecutive years, with $11.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income changed N/A to $11.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $52.9 million, a N/A change, with the full-year FY2025 number at $48.4 million, down 6.04% from a year prior.
  • Non Operating Income was $11.9 million for Q4 2025 at Cytokinetics, up from $10.2 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $17.1 million in Q3 2024 to a low of -$377000.0 in Q4 2021.
  • A 5-year average of $6.2 million and a median of $6.6 million in 2023 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: plummeted 117.57% in 2021, then skyrocketed 1693.94% in 2022.
  • Cytokinetics' Non Operating Income stood at -$377000.0 in 2021, then surged by 1670.03% to $5.9 million in 2022, then grew by 28.16% to $7.6 million in 2023, then soared by 124.81% to $17.1 million in 2024, then plummeted by 30.22% to $11.9 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Non Operating Income are $11.9 million (Q4 2025), $10.2 million (Q3 2025), and $13.7 million (Q1 2025).